- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04533373
Sensory Restoration After DIEP Flap Neurotization
The Effect of DIEP Flap Neurotization on Sensory Restoration After Breast Reconstruction
Common goals of breast reconstruction include obtaining satisfactory breast symmetry, softness, and appropriate size and shape. Advances in surgical techniques have prompted a new goal: achieving breast sensation after reconstructive surgery. This desire has led the surgical community to investigate operative techniques for achieving this goal. However, few studies have examined the effectiveness of breast sensory restoration.
Sensory nerves are nerves responsible for sensation from skin. When a sensory nerve is cut, sensation is lost to the area supplied by the nerve. In the case of Breast reconstruction this involves the nerves supplying the skin overlying breast(s). 'Neurotization' refers to regeneration of the nerve after it has been cut. This means that the cut nerve is being repaired in order to restore its function. In Neurotization this repair is carried out using a new "source". In this case, the investigators want to restore function of the nerves that supply the skin overlying the breast(s).
The investigators will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.
The Avance® Nerve graft is a nerve graft material that has been produced by Axogen, Inc. The graft is made by processing donated human nerves. This graft is used during neurotization to bridge the gap and join the nerve from the abdominal tissue to the nerve in the chest wall. The use of the graft helps the body to attach these 2 nerves and improves nerve repair.
When neurotization is done without the nerve graft there is a possibility that the surgeon may require extra nerve material to join the 2 nerves. Traditionally, in this case the surgeon would have to obtain a separate donor nerve from another part of the patient's body. This technique carries the risk of complications to part of the body that the separate donor nerve was obtained from - loss of sensation, infection or neuroma formation (an abnormal growth of nerve tissue that can cause pain, burning or tingling sensation, numbness). The Avance nerve graft avoids the need for the additional donor nerve and the possible complications associated with it.
The Avance® Nerve Graft is currently being used in some women during breast reconstruction surgery, however the effectiveness of this procedure in improving the restoration of sensation has not been proven.
Women undergoing reconstruction of one breast and at the same time using the women's own tissue as part of standard clinical care, may join.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rafael Tinogco
- Phone Number: 443-287-6012
- Email: rtiongc1@jhmi.edu
Study Contact Backup
- Name: Carisa M Cooney, MPH
- Phone Number: 443-287-4629
- Email: ccooney3@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Hospital
-
Contact:
- Rafael Tiongco
- Email: rtiongc1@jhmi.edu
-
Contact:
- Carisa M Cooney, MPH
- Email: ccooney3@jhmi.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All patients presenting to Johns Hopkins who have had or will have mastectomy (therapeutic or prophylactic) and are planning to undergo unilateral mastectomy followed by breast reconstruction with autologous deep inferior epigastric perforator flap (DIEP) will be included.
These patients will then be randomized in either of two treatment modalities:
- Treatment Modality 1: Breast reconstruction with DIEP flap and neurotization.
- Treatment Modality 2: Breast reconstruction with DIEP flap but without neurotization.
- 18 years of age and older
- The patient is aware of the nature of her malignancy if a malignancy has been diagnosed; understands the study purpose, requirements, and risks; and is able and willing to sign an informed consent.
Exclusion Criteria:
- Autologous reconstruction where the flap is buried.
- Exclusion criteria will encompass any patient with: diabetic neuropathy, thyroid disorders, collagen vascular disease, alcoholism, pernicious anemia, or any other severe underlying peripheral neuropathy including chemotherapy-induced neuropathy or neuropathy induced by other medications.
- Pregnant or lactating women will be excluded from this study.
- Women with recurrent breast cancer will be excluded.
- Women with previous reconstructive procedures or who have previously undergone lumpectomy with radiation will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neurotized Patients
Neurotization will be performed at the time of reconstruction.
|
We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect.
Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.
|
No Intervention: Non-Neurotized Patients
No Neurotization will be performed at the time of reconstruction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-month Breast sensation as assessed by the AcroValTM device
Time Frame: 12-months after DIEP Flap neurotization
|
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
|
12-months after DIEP Flap neurotization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Breast sensation at 6 months as assessed by the AcroValTM device
Time Frame: 6 months after DIEP flap breast reconstruction
|
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
|
6 months after DIEP flap breast reconstruction
|
Breast sensation at 18 months as assessed by the AcroValTM device
Time Frame: 18 months after DIEP flap breast reconstruction
|
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
|
18 months after DIEP flap breast reconstruction
|
Breast sensation at 24 months as assessed by the AcroValTM device
Time Frame: 24 months after DIEP flap breast reconstruction
|
Breast sensation, measured in cutaneous thresholds using the AcroValTM device.
|
24 months after DIEP flap breast reconstruction
|
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 6 months after DIEP flap breast reconstruction
|
The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction. |
6 months after DIEP flap breast reconstruction
|
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 12 months after DIEP flap breast reconstruction
|
The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction. |
12 months after DIEP flap breast reconstruction
|
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 18 months after DIEP flap breast reconstruction
|
The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction. |
18 months after DIEP flap breast reconstruction
|
Breast-specific health-related quality of life using the Breast-Q®
Time Frame: 24 months after DIEP flap breast reconstruction
|
The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction. |
24 months after DIEP flap breast reconstruction
|
General health-related quality of life using the SF-12
Time Frame: 6 months after DIEP flap breast reconstruction
|
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey.
It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score.
Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
|
6 months after DIEP flap breast reconstruction
|
General health-related quality of life using the SF-12
Time Frame: 12 months after DIEP flap breast reconstruction
|
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey.
It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score.
Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
|
12 months after DIEP flap breast reconstruction
|
General health-related quality of life using the SF-12
Time Frame: 18 months after DIEP flap breast reconstruction
|
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey.
It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score.
Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
|
18 months after DIEP flap breast reconstruction
|
General health-related quality of life using the SF-12
Time Frame: 24 months after DIEP flap breast reconstruction
|
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey.
It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score.
Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
|
24 months after DIEP flap breast reconstruction
|
Change in breast sensation as assessed by the AcroValTM device
Time Frame: Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction
|
Change in breast sensation from baseline, measured in cutaneous thresholds using the AcroValTM device.
|
Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction
|
Change in breast-specific health-related quality of life using the Breast-Q®
Time Frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
|
The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction. |
Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
|
Change in general health-related quality of life using the SF-12
Time Frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
|
The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey.
It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score.
Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.
|
Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gedge D Rosson, MD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB00167074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on DIEP Flap Neurotization
-
University of Wisconsin, MadisonNot yet recruitingBreast Reconstruction | Neurotization
-
Aalborg University HospitalCompletedBreast Neoplasms | Intraabdominal HypertensionDenmark
-
Vastra Gotaland RegionGöteborg UniversityRecruiting
-
University of ManitobaKeeping Abreast CharityCompletedDIEP Flap Breast Reconstruction | SIEA Flap Breast ReconstructionCanada
-
Vastra Gotaland RegionRecruitingBreast CancerSweden
-
Assistance Publique - Hôpitaux de ParisINSERM Bichat hospitalNot yet recruiting
-
The National Institute of LymphologyThe DrMarga Practice Group; The Center for Restorative Breast Surgery, LLCUnknownBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired LymphedemaUnited States
-
University of ManitobaEnrolling by invitation
-
Maastricht University Medical CenterCompleted
-
Stanford UniversityTerminatedNeurotrophic Keratitis | Neurotrophic Corneal Ulcer | Cranial Nerve V DiseasesUnited States